NAUT — Nautilus Biotechnology Cashflow Statement
0.000.00%
Last trade - 00:00- $233.66m
- $102.24m
- 46
- 35
- 91
- 59
Annual cashflow statement for Nautilus Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -15.6 | -50.3 | -57.9 | -63.7 | -70.8 |
| Depreciation | |||||
| Non-Cash Items | 2.3 | 10.1 | 11.7 | 13.3 | 15.1 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.39 | -0.022 | -0.788 | -3.22 | -5.46 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -14 | -39.2 | -45.8 | -51.7 | -59.1 |
| Capital Expenditures | -0.921 | -2.27 | -2.32 | -2.44 | -2.12 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -24.4 | -137 | -23.4 | -41.3 | 68.4 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -25.3 | -139 | -25.7 | -43.7 | 66.3 |
| Financing Cash Flow Items | 75.9 | 327 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 75.9 | 327 | 0.562 | 0.368 | 1.14 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 36.6 | 149 | -71 | -95.1 | 8.25 |